Mesna Injection
Function and Efficacy
This product is a compound containing cysteine, which can combine with the toxic metabolites of repeatedly activated cyclophosphamide or ifosfamide to form non-toxic products that are quickly excreted from the body through urine, preventing urinary system damage such as hemorrhagic cystitis caused by the use of the above anticancer drugs. Because the excretion rate of this product is faster than that of cyclophosphamide, ifosfamide and their metabolites, it should be used repeatedly.
Ingredients
The main ingredient of this product is: mesna.
| Name | Description | Content | CAS NO. | Manufacturer |
|---|---|---|---|---|
| MesnaIngredients |
This product is a compound containing cysteine, which can combine with the toxic metabolites of repeatedly activated cyclophosphamide or ifosfamide to form non-toxic products that are quickly excreted from the body through urine, preventing urinary system damage such as hemorrhagic cystitis caused by the use of the above anticancer drugs. Because the excretion rate of this product is faster than that of cyclophosphamide, ifosfamide and their metabolites, it should be used repeatedly. More |
19767-45-4 | 17 |
Indication
This product can prevent urinary epithelial toxicity such as hemorrhagic cystitis caused by high-dose ifosfamide or cyclophosphamide for tumor chemotherapy. It works together with anti-tumor chemotherapy drugs ifosfamide or cyclophosphamide as a urinary system protector.
Usage and Dosage
The commonly used dose of this product is 20% of the dose of cyclophosphamide, ifosfamide, and clofosamide, intravenously or intravenously, and the administration time is 0 hours (the same time as the cytostatics), 4 hours later, and 8 hours later, for a total of 3 times. For children, the number of doses should be more frequent (for example, 6 times) and at shorter intervals (for example, 3 hours). When using cyclophosphamide for continuous intravenous drip, a large dose of this product is injected intravenously at 0 hours of treatment, and then this product is added to the cyclophosphamide infusion and administered simultaneously (the dose of this product can be as high as 100% of the dose of cyclophosphamide). Use this product continuously for about 6 to 12 hours after the infusion is used up (the dose can be as high as 50% of the dose of cyclophosphamide) to protect the urethra.
Adverse Reactions
Venous irritation and allergic reactions (such as skin and mucosal reactions) are rare. When a single dose of this product exceeds 60 mg/kg body weight, nausea, vomiting, cramping abdominal pain and diarrhea may occur.
Drug Interactions
In test tube experiments, this product is incompatible with cisplatin and nitrogen mustard.
Storage
Keep away from light and store in a sealed container.
Packaging Specification
2ml:0.2g
Manufacturer
Qilu Pharmaceutical (Hainan) Co., Ltd.
-
Founded in:
2005-10-18 -
Address:
No. 273-A, Nanhai Avenue, National High-tech Zone, Haikou City -
Tax NO.:
91460000780701210W -
Registered Funds:
40 million yuan -
Website:
-
Email: